Results 51 to 60 of about 5,730 (206)

Korszakváltás a krónikus C-vírus hepatitis terápiájában – új direkt ható antivirális szerek [PDF]

, 2015
Absztrakt A krónikus C-vírus hepatitis kezelés nélkül 15–25 év alatt májzsugort, májelégtelenséget, májrákot okozhat.
Halász, Tünde, Horváth, Gábor, Hunyady, Béla, Makara, Mihály   +3 more
core   +1 more source

Hepatitis C Eradication Improves Oncologic and Clinical Outcomes in Patients Treated With Atezolizumab Plus Bevacizumab

Liver International, Volume 45, Issue 10, October 2025.
ABSTRACT Background and Aims Hepatitis C virus (HCV) is a key driver of hepatocellular carcinoma (HCC). However, the impact of HCV eradication on systemic therapy remains unclear. We aimed to assess the safety and efficacy of direct‐acting antivirals (DAA) in patients treated with Atezolizumab plus Bevacizumab (AtezoBev).
Leonardo Stella, Giuseppe Cabibbo, Ciro Celsa, Roberta Ciccia, Alba Sparacino, Fabio Piscaglia, Francesco Tovoli, Andrea Arleo, Bernardo Stefanini, Massimo Iavarone, Roberta D'Ambrosio, Lucia Cerrito, Maria Pallozzi, Francesco Santopaolo, Fabio Marra, Claudia Campani, Chiara Mazzarelli, Raffaella Viganò, Raffaella Tortora, Alessio Aghemo, Stella De Nicola, Tiziana Pressiani, Lorenza Rimassa, Sherrie Bhoori, Salvatore Corallo, Laura Maiocchi, Andrea Martini, Caterina Soldà, Francesco Paolo Russo, Antonio Gasbarrini, Francesca Romana Ponziani   +30 more
wiley   +1 more source

The Real-World Safety and Efficacy of Daclatasvir and Asunaprevir for Elderly Patients

Gut and Liver, 2018
Background/AimsAlthough daclatasvir with asunaprevir was approved in Japan for interferon ineligible or intolerant patients, patients aged ≥75 years were excluded in the phase III trial. The present study aimed to evaluate the safety and efficacy of this
Shinya Taki, Hideyuki Tamai, Yoshiyuki Ida, Naoki Shingaki, Akira Kawashima, Ryo Shimizu, Kosaku Moribata, Takao Maekita, Mikitaka Iguchi, Jun Kato, Taisei Nakao, Masayuki Kitano   +11 more
doaj   +1 more source

Microbial translocation and T cell activation are modified by direct-acting antiviral therapy in HCV-infected patients [PDF]

, 2018
BACKGROUND: Microbial translocation from the gut lumen has been involved in the pathogenesis of liver damage in hepatitis C virus (HCV) infection. AIM: To investigate the impact of direct-acting antiviral treatment on microbial translocation and T ...
Baroncelli, Silvia, DE SANTIS, Adriano, GINANNI CORRADINI, Stefano, Lattanzi, Barbara, Lupo1, Marinella, Maria Galluzzo, Clementina, Mennini, Gianluca, Merli, Manuela, Michelini, Zuleika, Palmisano, Lucia, Rossi, Massimo   +10 more
core   +1 more source

Harnessing Viral Proteases for Cellular and Molecular Engineering

Chemistry–Methods, Volume 5, Issue 9, September 2025.
Engineered viral proteases (VIPs) provide programmable control of protein function with high specificity and low toxicity. Integrated with chemogenetic and optogenetic modules, these VIP systems enable logic gate manipulation for targeted regulation of cell signaling, gene expression, protein secretion, and degradation, thereby offering versatile ...
Mingguang Cui, Tien‐Hung Lan, Yubin Zhou   +2 more
wiley   +1 more source

How Clinical Pharmacology Can Support Clinical Trial Diversity and Inclusion

Clinical and Translational Science, Volume 18, Issue 9, September 2025.
ABSTRACT Enrolling diverse populations during early clinical trial development and planning for diversity plans could be challenging. In 2024, the Diversity and Inclusion Clinical Pharmacology Leadership Group Working Group (D&I CPLG WG) from The International Consortium for Innovation and Quality in Pharmaceutical Development (IQ) collaborated with ...
Michael Z. Liao, Aarti Sawant, Brian Corrigan, Sebastian Haertter, Yasuto Otsubo, Islam R. Younis, Sreeneeranj Kasichayanula, Rashmi Mehta   +7 more
wiley   +1 more source

New treatments for genotype 1 chronic hepatitis C – focus on simeprevir

Therapeutics and Clinical Risk Management, 2014
Tatsuo Kanda, Shingo Nakamoto, Shuang Wu, Osamu Yokosuka Department of Gastroenterology and Nephrology, Graduate School of Medicine, Chiba University, Chiba, Japan Abstract: Chronic hepatitis C virus (HCV) infection causes end-stage liver diseases and ...
Kanda T, Nakamoto S, Wu S, Yokosuka O
doaj  

Update on hepatitis C virus resistance to direct-acting antiviral agents [PDF]

, 2014
Review[Abstract] Resistance to direct-acting antiviral (DAA) agents against hepatitis C virus (HCV) infection is driven by the selection of mutations at different positions in the NS3 protease, NS5B polymerase and NS5A proteins.
Cachay, Edward, Castro-Iglesias, Ángeles, Mena, Álvaro, Pedreira, José D., Poveda, Eva, Wyles, David L.   +5 more
core   +2 more sources

Acute liver disorders in the third trimester—AFLP, HELLP and infectious hepatitis—update on pathology, diagnosis and management

The Obstetrician &Gynaecologist, Volume 27, Issue 3, Page 180-196, July 2025.
Key content The epidemiology and pathophysiology of AFLP, HELLP syndrome and infectious viral hepatitis in late pregnancy. Clinical presentation, diagnosis and management of these conditions. Complications (maternal and fetal) and how these can be managed. The role of a multidisciplinary team in management.
Victor N. Chilaka, Mohammed Bashir, Theodore Ngatchu, Badreldeen Ahmed, Justin C. Konje   +4 more
wiley   +1 more source

Simeprevir for the treatment of hepatitis C virus infection

Pharmacogenomics and Personalized Medicine, 2014
Laure Izquierdo,1 François Helle,1 Catherine François,1,2 Sandrine Castelain,1,2 Gilles Duverlie,1,2 Etienne Brochot1,2 1Virology Research Unit, Jules Verne University of Picardie, 2Department of Virology, Amiens University Hospital, Amiens,
Izquierdo L, Helle F, François C, Castelain S, Duverlie G, Brochot E   +5 more
doaj